Global Amisulpride (CAS 71675-85-9) Market Size By Type (50mg/Tablet, 200mg/Tablet), By Application (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2023 to 2032

The Global Amisulpride (CAS 71675-85-9) Market was valued at USD 527.4 million in 2023 and is projected to reach USD 872.6 million by 2031, expanding at a CAGR of 6.5% during the forecast period from 2023 to 2031. The growth is primarily driven by the rising prevalence of schizophrenia and other psychotic disorders globally, increased awareness and diagnosis rates, and ongoing research into expanded indications such as depression and bipolar disorder. Amisulpride, an antipsychotic primarily used to manage schizophrenia, is gaining traction due to its relatively favorable side-effect profile and efficacy in both acute and maintenance therapy.

Drivers

1. Rising Prevalence of Psychiatric Disorders:

Global mental health burden is increasing, particularly for conditions like schizophrenia, depression, and bipolar disorder. The therapeutic efficacy of amisulpride in managing positive and negative symptoms makes it a preferred treatment choice, thus driving demand.

2. Expanding Geriatric Population:

Older adults are more prone to psychiatric disorders. With global aging trends, the demand for antipsychotic medications such as amisulpride is expected to rise significantly.

3. Increased Focus on Mental Health:

Growing public and governmental focus on mental healthcare, coupled with increasing funding and policy support, is boosting diagnosis and treatment rates—contributing to market growth.

Restraints

1. Side Effects and Regulatory Restrictions:

Although amisulpride is generally well-tolerated, it is associated with side effects like weight gain, extrapyramidal symptoms, and hyperprolactinemia, which may limit its use. Additionally, varying regulatory approvals across countries may hinder global market penetration.

2. Generic Competition:

Patent expirations and the widespread availability of generic versions at lower prices can restrain revenue growth for branded formulations.

Opportunity

1. Research on Expanded Indications:

Emerging research into the efficacy of amisulpride in conditions beyond schizophrenia, such as major depressive disorder, provides a potential avenue for market expansion.

2. Growth in Emerging Markets:

Rising healthcare investments and improving access to psychiatric care in regions such as Asia-Pacific, Latin America, and the Middle East are expected to create lucrative growth opportunities for market players.

Market by System Type Insights

Based on formulation type, the oral tablets segment held the largest share of the global amisulpride market in 2023. Tablets are favored for their convenience, ease of administration, and widespread availability in both generic and branded forms. However, the injectable segment is projected to grow at the fastest rate during the forecast period, especially for acute inpatient management in psychiatric facilities.

Market by End-use Insights

In terms of end-use, hospitals dominated the market in 2023, accounting for over 45% of the revenue share. Hospitals often manage acute psychiatric episodes and provide controlled environments for medication administration. The retail pharmacy segment is also growing rapidly, driven by improved outpatient care and growing prescription rates in community settings.

Market by Regional Insights

Geographically, Europe accounted for the largest market share in 2023, supported by high awareness, established psychiatric care frameworks, and wide access to amisulpride formulations. Asia-Pacific, however, is poised to register the highest CAGR, fueled by increased healthcare access, growing mental health awareness, and expanding pharmaceutical infrastructure in countries such as India and China.

Competitive Scenario

Key players operating in the Global Amisulpride (CAS 71675-85-9) Market include Sanofi, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Jubilant Life Sciences, Aurobindo Pharma, and Alkem Laboratories. These companies are engaged in strategies such as regulatory approvals, capacity expansion, strategic partnerships, and R&D for new indications. For instance:

In 2023, Teva expanded its generic amisulpride line across multiple European countries.

In 2024, Aurobindo Pharma received FDA clearance for its extended-release injectable formulation of amisulpride.

Scope of Work – Global Amisulpride (CAS 71675-85-9) Market

Key Market Developments

2023: Teva launched a portfolio of generic amisulpride tablets in Western Europe.

2024: Aurobindo Pharma received US FDA approval for a novel injectable amisulpride formulation targeting inpatient use.

2025: Intas Pharmaceuticals announced investment in AI-driven clinical trials for amisulpride’s efficacy in bipolar disorder.

FAQs

1) What is the current market size of the Global Amisulpride (CAS 71675-85-9) Market?

The market was valued at USD 527.4 million in 2023.

2) What is the major growth driver of the Global Amisulpride (CAS 71675-85-9) Market?

The major growth driver is the rising prevalence of psychiatric disorders and expanding mental health treatment accessibility.

3) Which is the largest region during the forecast period in the Global Amisulpride (CAS 71675-85-9) Market?

Europe accounted for the largest market share in 2023, but Asia-Pacific is expected to grow the fastest.

4) Which segment accounted for the largest market share in the Global Amisulpride (CAS 71675-85-9) Market?

The oral tablets segment held the largest share by formulation type.

5) Who are the key market players in the Global Amisulpride (CAS 71675-85-9) Market?

Key players include Sanofi, Teva Pharmaceuticals, Intas, Aurobindo Pharma, Jubilant Life Sciences, and Alkem Laboratories.